Oral or intravenous trimethoprim-sulfamethoxazole therapy for shigellosis
Related Experiment Video
Updated: Oct 24, 2026

Parabiosis in Mice: A Detailed Protocol
Published on: October 6, 2013
Abstract:
A review of the literature concerning shigellosis treated with trimethoprim-sulfamethoxazole (TMP-SMZ) revealed comparative studies of 149 cases and noncomparative studies of 147 cases. Bacteriologic and clinical success rates were greater than or equal to 90% and TMP-SMZ compared favorably with alternative drug therapy. In the present study TMP-SMZ was given intravenously as initial therapy to 11 children hospitalized for severe shigella colitis. Bacteriologic and clinical responses were comparable to those observed with oral TMP-SMZ therapy. Pharmacokinetic studies revealed substantial differences between the responses of these children and those reported for adult patients; a higher ratio of SMZ to TMP (50:1) was found in children. It is concluded that TMP-SMZ is effective therapy for shigellosis and is the drug of choice in areas where ampicillin resistance is prevalent.
Related Concept Videos
Prevention of Further Absorption of Poison
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
Pharmaceutical Poisoning: Treatment Strategies
Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care
Acute Pyelonephritis II: Diagnostic Studies and Management
Antiprotozoal Agents

